MRUS - Merus drops as RBC Capital Markets points to insufficient data in update for cancer trial

Yesterday, after the close, Merus (MRUS) updated interim data for its bispecific antibody zenocutuzumab (Zeno) in a phase 1/2 eNRGY trial targeting patients with NRG1+ cancers.The data was included in an abstract related to a presentation at the upcoming American Society of Clinical Oncology ((ASCO)) 2021 Annual Meeting.The trial consisted of three cohorts with NRG1+ cancers: pancreatic, non-small cell lung cancer, and other solid tumors.In the cohort of pancreatic cancer, the confirmed partial responses were seen in 4 of 10 patients (40% ORR). The loss of ~15.6% today might suggest that the results have not met the expectations.Despite the promising data in the cohort of pancreatic cancer, the confirmed partial responses were seen in nine patients (27% ORR) when 33 patients out of 55 patients who were treated with Zeno were evaluable for response.Issuing an update, RBC Capital Markets, which has an outperform rating on the stock with the price target of

For further details see:

Merus drops as RBC Capital Markets points to insufficient data in update for cancer trial